Although HER2-targeting drugs (e.g., trastuzumab and lapatinib) have been reported to regulate MCL1 activity via distinct mechanisms (transcriptionally or translationally) in other cancer types [50–52], their effects in GC cells have not been well studied. Here, ERBB2 is linked to cancer.